Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AIMDW NASDAQ:ATNFW NASDAQ:LBPSW NASDAQ:RVPHW On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIMDWAinos$0.24+5.1%$0.26$0.03▼$0.95N/AN/A11,958 shs1,876 shsATNFW180 Life Sciences$0.08+33.6%$0.15$0.00▼$0.62N/AN/A501,334 shs338,242 shsLBPSW4D pharma$0.00$0.04▼$1.29N/AN/A20,931 shsN/ARVPHWReviva Pharmaceuticals$0.07+1.6%$0.05$0.02▼$0.78N/AN/A68,953 shs75,193 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIMDWAinos+26.34%+68.99%+14.15%+90.25%+281.14%ATNFW180 Life Sciences0.00%-25.22%-67.26%+646.84%+646.93%LBPSW4D pharma0.00%0.00%0.00%0.00%0.00%RVPHWReviva Pharmaceuticals+32.99%+52.98%-7.90%+94.24%-30.33%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIMDWAinos$0.24+5.1%$0.26$0.03▼$0.95N/AN/A11,958 shs1,876 shsATNFW180 Life Sciences$0.08+33.6%$0.15$0.00▼$0.62N/AN/A501,334 shs338,242 shsLBPSW4D pharma$0.00$0.04▼$1.29N/AN/A20,931 shsN/ARVPHWReviva Pharmaceuticals$0.07+1.6%$0.05$0.02▼$0.78N/AN/A68,953 shs75,193 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIMDWAinos+26.34%+68.99%+14.15%+90.25%+281.14%ATNFW180 Life Sciences0.00%-25.22%-67.26%+646.84%+646.93%LBPSW4D pharma0.00%0.00%0.00%0.00%0.00%RVPHWReviva Pharmaceuticals+32.99%+52.98%-7.90%+94.24%-30.33%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAIMDWAinos 0.00N/AN/AN/AATNFW180 Life Sciences 0.00N/AN/AN/ALBPSW4D pharma 0.00N/AN/AN/ARVPHWReviva Pharmaceuticals 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAIMDWAinos$110.87KN/AN/AN/AN/AN/AATNFW180 Life SciencesN/AN/AN/AN/AN/AN/ALBPSW4D pharma$522KN/AN/AN/AN/AN/ARVPHWReviva PharmaceuticalsN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAIMDWAinosN/AN/A0.00∞N/AN/AN/AN/AN/AATNFW180 Life SciencesN/AN/A0.00∞N/AN/AN/AN/AN/ALBPSW4D pharmaN/AN/A0.00N/AN/AN/AN/AN/AN/ARVPHWReviva PharmaceuticalsN/AN/A0.00∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAIMDWAinosN/AN/AN/AN/AN/AATNFW180 Life SciencesN/AN/AN/AN/AN/ALBPSW4D pharmaN/AN/AN/AN/AN/ARVPHWReviva PharmaceuticalsN/AN/AN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAIMDWAinosN/AATNFW180 Life SciencesN/ALBPSW4D pharmaN/ARVPHWReviva PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipAIMDWAinosN/AATNFW180 Life SciencesN/ALBPSW4D pharmaN/ARVPHWReviva PharmaceuticalsN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAIMDWAinos40N/AN/ANot OptionableATNFW180 Life Sciences7N/AN/ANot OptionableLBPSW4D pharmaN/AN/AN/ANot OptionableRVPHWReviva Pharmaceuticals5N/AN/ANot OptionableRVPHW, ATNFW, LBPSW, and AIMDW HeadlinesRecent News About These CompaniesReviva to Participate in the 4th Annual Roth Healthcare Opportunities ConferenceOctober 2, 2025 | finance.yahoo.comReviva Pharmaceuticals Holdings (RVPH) Price Target Decreased by 18.61% to 5.95September 30, 2025 | msn.comReviva Pharmaceuticals price target lowered to $2 from $5 at MaximAugust 15, 2025 | msn.comReviva Pharmaceuticals reports Q2 EPS (12c) vs. (26c) last yearAugust 14, 2025 | msn.comRVPHW Reviva Pharmaceuticals Holdings, Inc. WT EXP 122525May 30, 2025 | seekingalpha.comRVPH: 1Q:25 ResultsMay 22, 2025 | finance.yahoo.comReviva Pharmaceuticals Reports Q1 2025 Financial ResultsMay 20, 2025 | tipranks.comReviva Pharmaceuticals Reports Completion of Brilaroxazine Long-Term OLE Trial and Upcoming Phase 3 RECOVER-2 Trial InitiationMay 17, 2025 | nasdaq.comReviva Pharmaceuticals price target lowered to $8 from $15 at D. Boral CapitalApril 2, 2025 | markets.businessinsider.comReviva Pharmaceuticals Reports 2024 Financial ResultsApril 1, 2025 | tipranks.comUncover the Reason: Why Reviva Pharmaceuticals Holdings Inc (RVPH) Stock Is Trading 213.33% Above Its 52-Week Low?January 13, 2025 | bovnews.comBReviva Pharmaceuticals initiated with a Buy at Roth MKMJanuary 11, 2025 | markets.businessinsider.comMaxim Group Upgrades Reviva Pharmaceuticals Holdings (RVPH)January 11, 2025 | msn.comReviva Pharmaceuticals Holdings Inc (RVPH) Stock Sees Market Value Hit $93.63 million: What Are the Implications?January 3, 2025 | bovnews.comBReviva Pharmaceuticals Holdings Inc (RVPH) Stock: Greater Than Its Current Valuation?January 1, 2025 | bovnews.comBReviva Pharmaceuticals Holdings Inc (RVPH) Stock: Unveiling Its Hidden StrengthsDecember 28, 2024 | bovnews.comBWhat’s Driving Reviva Pharmaceuticals Holdings, Inc. (RVPH) Stock’s 56.99% Surge Over the Past Month?December 26, 2024 | bovnews.comBReviva Pharmaceuticals Shares Slide Premarket After Stock OfferingDecember 17, 2024 | marketwatch.comROTH MKM Issues Buy Rating for Reviva Pharmaceuticals Holdings, Inc. (RVPH) StockDecember 17, 2024 | bovnews.comBWhat’s Behind the 11.90% Gain in Reviva Pharmaceuticals Holdings, Inc. (RVPH) Stock? Find Out Now!December 12, 2024 | bovnews.comBMedia Sentiment Over TimeRVPHW, ATNFW, LBPSW, and AIMDW Company DescriptionsAinos NASDAQ:AIMDW$0.24 +0.01 (+5.08%) As of 11:23 AM EasternAinos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women's health, pneumonia, Ainos Pen, AI Nose, and other products. Ainos, Inc. was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. The company was incorporated in 1984 and is based in San Diego, California.180 Life Sciences NASDAQ:ATNFW$0.08 +0.02 (+33.56%) As of 10/6/2025180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed phase 2a and phase 2b proof-of-concept clinical trials for early-stage Dupuytren's Contracture; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, that focuses on alpha 7 nicotinic acetylcholine receptor. 180 Life Sciences Corp. is headquartered in Palo Alto, California.4D pharma NASDAQ:LBPSW4D pharma plc, together with its subsidiaries, engages in the research, development, and production of live biotherapeutic products. The company develops therapeutic candidates, such as MRx0518; MRx-4DP000 for the treatment of asthma and COVID-19; MRx0029 the treatment of central nervous system disorders; Blautix for irritable bowel syndrome; and Thetanix for pediatric crohn's disease. It also develops products candidates, including MRx1299 for solid tumors, MRx0005 for neurodegeneration, MRx0006 for rheumatoid arthritis, and MRx0002 for multiple sclerosis. The company develops MicroRx platform to discover new LBP candidates for major diseases. 4D pharma plc has a collaboration agreement with Merck & Co., Inc. to conduct a clinical trial evaluating the combination of Keytruda and MRx0518 in patients with solid tumors. The company was formerly known as Schosween 18 Limited. 4D pharma plc was incorporated in 2014 and is headquartered in Leeds, the United Kingdom.Reviva Pharmaceuticals NASDAQ:RVPHW$0.07 +0.00 (+1.56%) As of 12:43 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is brilaroxazine (RP5063), which is in Phase III clinical trials for use in the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis. It is also developing RP1208 that is in pre-clinical development studies for the treatment of depression and obesity. The company was founded in 2018 and is based in Cupertino, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Joby's Stock Rallies as Public Flights Validate Global Game Plan SharkNinja Is Flashing a Buy Signal the Market Is Ignoring Why Semtech Stock Is Rallying After Its NVIDIA Setback Marvell Insiders Buy Shares—Should Investors Follow Suit? TrumpRx Brings Pfizer Into the Green—Is It a Buy? Behind D-Wave's Massive Week (And Why Rivals Also Popped) Eli Lilly Stock Soars on Trump Tariff Hopes and Pfizer Deal 2 Defense Stocks Riding 2025’s Massive Momentum Wave Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
